Compass Pathways (CMPS)

• Market cap: $330M
• 1 day: -4.56%
• 5 days: -13.80%
• 1 month: -19.46%
• 3 months: -15.64%
• 6 months: -50.90%
• Year to date: -14.22%
• 1 year: -66.60%
• 5 years: -87.72%
• 10 years: -87.72%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Employees: 166

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

13% more call options, than puts

Call options by funds: $1.42M | Put options by funds: $1.26M

2% more funds holding

Funds holding: 129 [Q3] → 131 (+2) [Q4]

7% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 29

4% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 27

2.7% less ownership

Funds ownership: 47.92% [Q3] → 45.22% (-2.7%) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

43% less capital invested

Capital invested by funds: $206M [Q3] → $118M (-$88.7M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $11 209% upside
• Avg. target: $22 525% upside
• High target: $45 1,164% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick Trucchio 26% 1-year accuracy 48 / 184 met price target	1,164% upside $45	Buy Reiterated	4 Mar 2025
Canaccord Genuity Sumant Kulkarni 23% 1-year accuracy 7 / 31 met price target	321% upside $15	Buy Maintained	28 Feb 2025
Stifel Paul Matteis 19% 1-year accuracy 3 / 16 met price target	209% upside $11	Buy Initiated	27 Feb 2025
RBC Capital Leonid Timashev 37% 1-year accuracy 15 / 41 met price target	406% upside $18	Outperform Reiterated	15 Jan 2025